Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerHomayoun Zargar, Peter C. Black, Joshua Griffin et al.|European Urology|2014Cited by 297
The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladderAlexander S. Baras, Trinity J. Bivalacqua, Charles G. Drake et al.|OncoImmunology|2016Cited by 174
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial CarcinomaAlexander S. Baras, George J. Netto, Nilay Gandhi et al.|PLoS ONE|2015Cited by 46
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomesNilay Gandhi, Trinity J. Bivalacqua, Alexander S. Baras et al.|Urologic Oncology Seminars and Original Investigations|2015Cited by 39
Blood Transfusion is Associated with Increased Perioperative Morbidity and Adverse Oncologic Outcomes in Bladder Cancer Patients Receiving Neoadjuvant Chemotherapy and Radical CystectomyHeather J. Chalfin, Trinity J. Bivalacqua, Nilay Gandhi et al.|Annals of Surgical Oncology|2016Cited by 37